Search results for "TIMP-1"

showing 7 items of 7 documents

BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.

2011

BRAFV600E is the most common mutation found in papillary thyroid carcinoma (PTC). Tissue inhibitor of metalloproteinases (TIMP-1) and nuclear factor (NF)-κB have been shown to play an important role in thyroid cancer. In particular, TIMP-1 binds its receptor CD63 on cell surface membrane and activates Akt signaling pathway, which is eventually responsible for its anti-apoptotic activity. The aim of our study was to evaluate whether interplay among these three factors exists and exerts a functional role in PTCs. To this purpose, 56 PTC specimens were analyzed for BRAFV600E mutation, TIMP-1 expression, and NF-κB activation. We found that BRAFV600E mutation occurs selectively in PTC nodules an…

MAPK/ERK pathwayAdultMaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismThyroid cancer TIMP-1 papillary thyroid cancerMutation MissenseGlutamic AcidGene Expression Regulation EnzymologicSettore MED/13 - EndocrinologiaPapillary thyroid cancerEndocrinologyDownregulation and upregulationInternal medicinemedicineTumor Cells CulturedGene silencingHumansGene Regulatory NetworksNeoplasm InvasivenessThyroid NeoplasmsProtein kinase BThyroid cancerTissue Inhibitor of Metalloproteinase-1ChemistryAkt/PKB signaling pathwayCarcinomaNF-kappa BValineMiddle Agedmedicine.diseaseCarcinoma PapillaryUp-RegulationGene Expression Regulation NeoplasticEndocrinologyCell Transformation NeoplasticOncologyAmino Acid SubstitutionThyroid Cancer PapillaryCancer researchDisease ProgressionFemaleV600ESignal TransductionEndocrine-related cancer
researchProduct

Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome.

2016

Obstructive sleep apnea syndrome (OSAS) is associated with an elevated risk of cardiovascular events and stroke. Matrix metalloproteinases (MMPs) are endopeptidases involved in extracellular matrix degradation and then in the development and progression of cardiovascular diseases. Our aim was to evaluate plasma levels of gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in a group of subjects with OSAS. We enrolled 48 subjects (36 men and 12 women; mean age 49.7 ± 14.68 yrs) with OSAS diagnosed with a 1-night cardiorespiratory study and then we subdivided these subjects into two subgroups according to the apnea/hypopnea index (AHI): Low (L = 21 subjects with AHI …

Malemedicine.medical_specialtyGelatinasesSettore MED/09 - Medicina InternaPhysiologyMMP-2; MMP-9; obstructive sleep apnea; TIMP-1; TIMP-2; Disease Progression; Female; Gelatinases; Humans; Male; Middle Aged; Sleep Apnea Obstructive; Tissue Inhibitor of Metalloproteinase-1; Physiology; Hematology; Cardiology and Cardiovascular Medicine; Physiology (medical)030204 cardiovascular system & hematologyMatrix metalloproteinaseGastroenterologyTIMP-203 medical and health sciencesTIMP-10302 clinical medicinePhysiology (medical)Internal medicinemedicineHumansStrokeobstructive sleep apneaOxygen saturation (medicine)Sleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-1MMP-2business.industryApneaCardiorespiratory fitnessHematologyMiddle Agedmedicine.diseasenervous system diseasesrespiratory tract diseasesObstructive sleep apneaEndocrinology030228 respiratory systemGelatinaseGelatinasesDisease ProgressionFemalemedicine.symptomMMP-9Settore MED/36 - Diagnostica Per Immagini E RadioterapiaCardiology and Cardiovascular MedicinebusinessHypopneaHumanClinical hemorheology and microcirculation
researchProduct

BRAFV660E mutation and Timp-1 hyper-expression in classical variants of papyllary thyroid carcinoma.

2009

BrafV600E Papillary thyroid carcinoma TIMP-1Settore MED/13 - Endocrinologia
researchProduct

BrafV600E mutation and hyperexpression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in papillary thyroid carcinoma

2009

Settore MED/06 - Oncologia MedicaTimp-1 braf thyroid carcinomaSettore MED/13 - Endocrinologia
researchProduct

Behaviour of the plasma concentration of gelatinases and their tissue inhibitors in subjects with venous leg ulcers.

2015

Venous leg ulcers are common in subjects with chronic venous insufficiency. The increased intraluminal pressure causes alteration of the skin microcirculation, leukocyte activation and release of proteolytic enzymes leading to ulceration. An impaired expression and activity of matrix metalloproteases (MMPs) and their tissue inhibitors (TIMPs) might influence extracellular matrix degradation and deposition in chronic venous ulcers with the failure of the healing process. Our aim was to evaluate plasma concentration of gelatinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in subjects with venous leg ulcers before and after the compression therapy. We enrolled 36 subjects (12 …

Ulcer healingMalemedicine.medical_specialtyGelatinasesSettore MED/09 - Medicina InternaPhysiologyChronic venous insufficiencyMatrix metalloproteinaseGastroenterologyMicrocirculationVaricose UlcerTIMP-2TIMP-1Physiology (medical)Internal medicinemedicineHumansAgedTissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-1MMP-2business.industryMMP-2; MMP-9; TIMP-1; TIMP-2; Venous leg ulcersLeg UlcerProteolytic enzymesHematologyVenous bloodmedicine.diseaseMatrix MetalloproteinasesSurgeryVenous leg ulcersVenous InsufficiencyGelatinasesPlasma concentrationMatrix Metalloproteinase 2FemaleMMP-9Cardiology and Cardiovascular Medicinebusiness
researchProduct

The function of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1) in several clinical conditions: Results and analysis of our surv…

2021

The goal of this research was to evaluate the plasma concentration of MMP-9 and its tissue inhibitor (TIMP-1) in different clinical conditions. It included several groups of subjects: 31 overweight subjects; 91 obese adults divided into two subgroups according to the BMI value (BMI 30–35 Kg/m2 and BMI > 35 Kg/m2); 90 subjects with metabolic syndrome (MS) divided into two subgroups (with and without diabetes mellitus); 100 subjects with preclinical carotid atherosclerosis (PCA) divided according to the number of cardiovascular risk factors and to the insulin resistance degree; 48 subjects with obstructive sleep apnoea syndrome (OSAS) divided according to the apnoea/hypopnea index (AHI); 2…

0301 basic medicineAdultmedicine.medical_specialtyPhysiologymedicine.medical_treatment030204 cardiovascular system & hematologyOverweightAdult CKD Humans metabolic syndrome Matrix Metalloproteinase 9 Metabolic Syndrome MMP-9 Obesity OSAS preclinical carotid atherosclerosis Sleep Apnea Obstructive TIMP-1 Tissue Inhibitor of Metalloproteinase-103 medical and health sciences0302 clinical medicineInsulin resistancePhysiology (medical)Diabetes mellitusInternal medicinemedicineHumansObesityDialysisMetabolic SyndromeSleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-1business.industryHematologymedicine.diseaseObesity030104 developmental biologyMatrix Metalloproteinase 9medicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessHypopneaKidney diseaseClinical hemorheology and microcirculation
researchProduct

Leukocyte subtypes, gelatinases, and their tissue inhibitors in a group of subjects with asymptomatic carotid atherosclerosis

2022

In a cohort of subjects with asymptomatic carotid atherosclerosis (ACA), we have evaluated the neutrophil and lymphocyte count and their ratio (NLR), the gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2). At baseline, no difference was observed between ACA subjects and subject control group regarding neutrophil and lymphocyte count while was evident in ACA subjects a significant increase in MMP-2, MMP-9 and TIMP-2 associated to a significant decrease in TIMP-1. Dividing the ACA according to the number of cardiovascular risk factors (CRFs) we have observed an increase in lymphocyte count in the subgroup with 3–5 CRFs. Evaluating the leukocyte subtypes according to…

Carotid Artery Diseasescardiovascular risk factorslymphocytesTissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-1PhysiologyHematologyTIMP-2Asymptomatic carotid atherosclerosisTIMP-1Matrix Metalloproteinase 9neutrophilsinsulin resistancePhysiology (medical)LeukocytesHumansMatrix Metalloproteinase 2Cardiology and Cardiovascular MedicinegelatinasesBiomarkersResearch ArticleClinical Hemorheology and Microcirculation
researchProduct